ES2629749T3 - Inmunidad tumoral - Google Patents

Inmunidad tumoral Download PDF

Info

Publication number
ES2629749T3
ES2629749T3 ES14197004.6T ES14197004T ES2629749T3 ES 2629749 T3 ES2629749 T3 ES 2629749T3 ES 14197004 T ES14197004 T ES 14197004T ES 2629749 T3 ES2629749 T3 ES 2629749T3
Authority
ES
Spain
Prior art keywords
tumor immunity
mfg
inhibitor
integrin
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14197004.6T
Other languages
English (en)
Inventor
Glenn Dranoff
Masahisa Jinushi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2629749T3 publication Critical patent/ES2629749T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Una composición que comprende un inhibidor de MFG-E8 y GM-CSF, en donde el inhibidor de MFG-E8 interfiere con la unión de MFG-E8 a una integrina o a la fosfatidilserina expresada en la superficie de una célula.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28

Claims (1)

  1. imagen1
ES14197004.6T 2006-10-04 2007-10-04 Inmunidad tumoral Active ES2629749T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82817706P 2006-10-04 2006-10-04
US828177P 2006-10-04

Publications (1)

Publication Number Publication Date
ES2629749T3 true ES2629749T3 (es) 2017-08-14

Family

ID=39268819

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14197004.6T Active ES2629749T3 (es) 2006-10-04 2007-10-04 Inmunidad tumoral

Country Status (5)

Country Link
US (2) US9492518B2 (es)
EP (2) EP2083852B1 (es)
CA (1) CA2664567C (es)
ES (1) ES2629749T3 (es)
WO (1) WO2008043018A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ555363A (en) 2007-05-24 2009-11-27 Pacific Edge Biotechnology Ltd Prognosis prediction for melanoma cancer
WO2009147781A1 (ja) 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
JP4686733B2 (ja) * 2008-06-02 2011-05-25 国立大学法人 東京大学 抗がん剤
WO2009147695A1 (ja) * 2008-06-02 2009-12-10 国立大学法人東京大学 抗がん剤
JP2011074093A (ja) * 2008-06-02 2011-04-14 Univ Of Tokyo 抗がん剤
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
PT2760471T (pt) 2011-09-30 2017-03-22 Dana Farber Cancer Inst Inc Péptidos terapêuticos
WO2013139956A1 (en) * 2012-03-22 2013-09-26 Thrombogenics Nv Antibodies abrogating cell binding to lactadherin
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
HRP20180359T1 (hr) 2013-01-07 2018-05-04 Institut National De La Santé Et De La Recherche Médicale (Inserm) Liječenje bolesti uporabom tolerogenskog farmaceutskog pripravka
NZ629816A (en) 2013-03-15 2017-07-28 Dana Farber Cancer Inst Inc Therapeutic peptides
CN106029694A (zh) 2013-12-06 2016-10-12 达纳-法伯癌症研究院公司 治疗性肽
CN113491766A (zh) 2014-03-14 2021-10-12 达纳－法伯癌症研究所公司 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
US9955318B1 (en) 2014-06-05 2018-04-24 Steelcase Inc. Space guidance and management system and method
WO2016104642A1 (ja) * 2014-12-25 2016-06-30 一般財団法人糧食研究会 乳化安定剤及びそれを用いた乳化安定化方法
WO2016161347A1 (en) * 2015-04-03 2016-10-06 Pharmacyclics Llc Combinations for generating tumor-specific immunological memory
WO2025110250A1 (ja) * 2023-11-24 2025-05-30 秀晃 田原 改変ｍｆｇ－ｅ８タンパク質

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5972337A (en) * 1990-11-01 1999-10-26 Cancer Research Fund Of Contra Costa 46 kilodalton human milk fat globule (HMFG) antigen, fragments and fusion protein
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
AU750414B2 (en) 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
AU771224B2 (en) * 1998-07-13 2004-03-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1004664A1 (en) * 1998-11-24 2000-05-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods using lactadherin or variants thereof
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
WO2001068709A1 (en) * 2000-03-14 2001-09-20 Idec Pharmaceuticals Corporation Antibodies that bind phosphatidyl serine and a method of their use
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
JP4160292B2 (ja) * 2001-11-20 2008-10-01 独立行政法人科学技術振興機構 生体内のアポトーシス細胞の除去促進剤及び除去阻害剤
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1615670A4 (en) 2003-04-01 2006-12-13 Intradigm Corp TARGETS FOR INHIBITING TUMOR GROWTH

Also Published As

Publication number Publication date
US9492518B2 (en) 2016-11-15
US20100189711A1 (en) 2010-07-29
EP2862579A1 (en) 2015-04-22
CA2664567A1 (en) 2008-04-10
US20170224793A1 (en) 2017-08-10
WO2008043018A1 (en) 2008-04-10
CA2664567C (en) 2016-04-26
EP2862579B1 (en) 2017-05-17
EP2083852B1 (en) 2014-12-10
EP2083852A1 (en) 2009-08-05
HK1206973A1 (en) 2016-01-22
EP2083852A4 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
ES2665917T3 (es) Endoxifeno para su uso en el tratamiento del cáncer
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
ES2588766T3 (es) Cartucho de cinta inteligente
ES2517899T3 (es) Herramienta de material cerámico en polvo prensado para su utilización en la formación de artículos moldeados
CA114230S (en) Tape cartridge
RU2008123590A (ru) Средство с мембраностабилизирующим эффектом
TH43186S1 (th) ตัวล็อคถังบรรจุก๊าซ
TH102857S (th) ตัวล็อคถังบรรจุก๊าซ
TH43187S1 (th) ตัวล็อคถังบรรจุก๊าซ
TH105232S (th) กระบอกกุญแจ
TH42882S1 (th) กระบอกกุญแจ
UY3571Q (es) Articulo exhibidor
TH110055S (th) แหวนล็อค
TH42944S1 (th) แหวนล็อค
TR200708720U (tr) Değişken yüzeyli kübik araç.
TH40223S1 (th) ตู้เสื้อผ้า
TH99415S (th) ตู้เสื้อผ้า
TH99824S (th) ตู้เสื้อผ้า
TH99416S (th) ตู้เสื้อผ้า
TH39427S1 (th) ตู้เสื้อผ้า
TH99413S (th) ตู้เสื้อผ้า
TH96476S (th) ตู้ใส่เสื้อผ้า
TH99414S (th) ตู้เสื้อผ้า
TH40221S1 (th) ตู้เสื้อผ้า
TH41217S1 (th) ตู้เสื้อผ้า